S&P 500 7,723.39 ▲ 46.62 (+0.61%) DOW 52,389.06 ▲ 27.48 (+0.05%) NASDAQ 26,480.43 ▲ 311.05 (+1.19%) US Markets Closed â€ĸ 04:09 PM ET

DRUG

Bright Minds Biosciences Inc.

Price Chart
Latest Quote

$54.02

+2.93 (+5.73%)
Current Price
Previous Close $51.09
Open $51.21
Day High $54.83
Day Low $49.89
Volume 59,375
Fetched: 2026-10-27T20:09:21
Stock Information
Note: Financial values converted from CAD to USD
Shares Outstanding 9.86M
Total Debt $47K
Cash Equivalents $219.13M
Net Income $-17.45M
Sector Healthcare
Industry Biotechnology
Market Cap $532.86M
EPS (TTM) $-2.05
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$196.19M
Income$-17.45M
Book/sh$22.22
Cash/sh$31.21
Employees26
Financial Ratios
Quick Ratio121.44
Current Ratio121.97
Debt/Eq0.02
Returns & Margins
ROA-13.50%
ROE-13.63%
Ownership
Insider Ownership11.49%
Institutional Ownership94.95%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-9.35
P/B2.43
Analyst Data
Recommendationstrong_buy
Target Price$154.03
Technical Indicators
SMA20$51.86
SMA50$60.79
SMA200$73.77
RSI53.71
ATR3.9523
Shares Float6.74M
Short Float11.60%
Short Ratio9.72
Volatility0.23
Rel Volume0.39
Performance History
Week-2.14%
Month+4.57%
Quarter-23.98%
6 Months-39.30%
YTD-35.27%
Year-11.70%
3 Years+3477.48%
5 Years+50.29%
10 Years+100.07%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-10-27 $54.02 59,375
2026-10-26 $51.09 89,100
2026-10-23 $52.48 57,100
2026-10-22 $52.69 221,300
2026-10-21 $50.44 156,300
2026-10-20 $55.20 94,700
2026-10-19 $53.82 156,300
2026-10-16 $51.30 56,000
2026-10-15 $54.21 121,500
2026-10-14 $50.71 199,400
2026-10-13 $51.36 246,600
2026-10-12 $54.01 134,600
2026-10-09 $54.05 98,400
2026-10-08 $52.00 67,900
2026-10-07 $52.00 688,800
2026-10-06 $48.25 107,700
2026-10-05 $49.79 55,900
2026-10-02 $50.69 154,900
2026-10-01 $49.21 166,900
2026-09-30 $49.82 79,800
2026-09-29 $49.74 96,800
2026-09-28 $51.66 91,900
About Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

📰 Latest News
No news articles available at the moment. Check back later for updates on DRUG.
Period:
Income Statement (Annual)
Metric 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Total Expenses $9,953,995 $2,015,974 $5,275,256 $10,694,967
Other Income Expense $134,815 $-6,650 $10,134 $7,250
Net Non Operating Interest Income Expense $1,085,179 $21,520 $0 $0
Operating Expense $9,953,995 $2,015,974 $5,275,256 $10,694,967
Other Operating Expenses $205,432 $140,827 $133,303 $173,603
Selling And Marketing Expense $306,855 $29,710 $85,286 $394,132
General And Administrative Expense $1,525,332 $1,002,693 $1,485,788 $1,427,804
Other Non Operating Income Expenses - - - $-173,603
Total Other Finance Cost - - - -
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-8,734,001 $-2,001,104 $-5,265,123 $-10,687,717
Net Interest Income $1,085,179 $21,520 $0 $0
Interest Income $1,085,179 $21,520 $0 $0
Normalized Income $-8,868,816 $-1,994,454 $-5,275,256 $-10,694,967
Net Income From Continuing And Discontinued Operation $-8,734,001 $-2,001,104 $-5,265,123 $-10,687,717
Net Income Common Stockholders $-8,734,001 $-2,001,104 $-5,265,123 $-10,687,717
Net Income $-8,734,001 $-2,001,104 $-5,265,123 $-10,687,717
Net Income Including Noncontrolling Interests $-8,734,001 $-2,001,104 $-5,265,123 $-10,687,717
Net Income Continuous Operations $-8,734,001 $-2,001,104 $-5,265,123 $-10,687,717
Pretax Income $-8,734,001 $-2,001,104 $-5,265,123 $-10,687,717
Interest Income Non Operating $1,085,179 $21,520 $0 $0
Operating Income $-9,953,995 $-2,015,974 $-5,275,256 $-10,694,967
Special Income Charges - $0 $0 $-1,428
Per Share
Diluted EPS $-1.27 $-0.46 $-1.41 $-4.33
Basic EPS $-1.27 $-0.46 $-1.41 $-4.33
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-10,033,912 $-1,956,933 $-5,233,647 $-10,697,905
Total Unusual Items $134,815 $-6,650 $10,134 $7,250
Total Unusual Items Excluding Goodwill $134,815 $-6,650 $10,134 $7,250
Reconciled Depreciation $54,898 $52,390 $51,743 $4,312
EBITDA (Bullshit earnings) $-9,899,097 $-1,963,584 $-5,223,514 $-10,690,655
EBIT $-9,953,995 $-2,015,974 $-5,275,256 $-10,694,967
Diluted Average Shares $4,912,192 $3,078,252 $2,656,603 $1,764,307
Basic Average Shares $4,912,192 $3,078,252 $2,656,603 $1,764,307
Diluted NI Availto Com Stockholders $-8,734,001 $-2,001,104 $-5,265,123 $-10,687,717
Gain On Sale Of Security $134,815 $-6,650 $10,134 $8,678
Research And Development $7,916,376 $842,744 $3,570,879 $8,699,427
Selling General And Administration $1,832,188 $1,032,403 $1,571,075 $1,821,936
Other Gand A $1,170,164 $650,034 $659,819 $1,356,787
Salaries And Wages $355,168 $352,659 $825,970 $71,017
Impairment Of Capital Assets - $0 $0 $1,428
Fetched: 2026-10-24
Balance Sheet (Annual)
Metric 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Assets
Net Tangible Assets $58,595,147 $3,953,966 $4,712,338 $7,529,290
Total Assets $60,292,487 $4,359,807 $4,912,921 $8,632,327
Total Non Current Assets $79,966 $84,029 $47,431 $99,174
Current Assets $60,212,521 $4,275,778 $4,865,490 $8,533,153
Prepaid Assets $705,550 $154,712 $19,777 $117,433
Receivables $295,009 $35,869 $26,411 $111,255
Taxes Receivable $149,920 $35,869 $26,411 $81,787
Accrued Interest Receivable $145,089 $0 - -
Cash Cash Equivalents And Short Term Investments $59,211,963 $4,085,196 $4,819,302 $8,304,466
Cash And Cash Equivalents $59,211,963 $4,085,196 $4,819,302 $8,304,466
Cash Equivalents $61,598 $61,598 $61,598 $61,598
Cash Financial $59,150,365 $4,023,598 $4,757,703 $8,242,868
Goodwill And Other Intangible Assets - - - $0
Other Receivables - - - $29,468
Debt
Total Debt $89,828 $84,959 $52,527 $99,922
Long Term Debt And Capital Lease Obligation $29,459 $28,265 $0 $51,409
Current Debt And Capital Lease Obligation $60,369 $56,695 $52,527 $48,513
Liabilities
Total Liabilities Net Minority Interest $1,697,340 $405,841 $200,583 $1,103,037
Total Non Current Liabilities Net Minority Interest $29,459 $28,265 $0 $51,409
Current Liabilities $1,667,881 $377,577 $200,583 $1,051,628
Payables And Accrued Expenses $1,607,513 $320,882 $148,055 $1,003,115
Payables $1,221,461 $291,064 $130,201 $890,147
Accounts Payable $1,221,461 $291,064 $130,201 $890,147
Equity
Common Stock Equity $58,595,147 $3,953,966 $4,712,338 $7,529,290
Total Equity Gross Minority Interest $58,595,147 $3,953,966 $4,712,338 $7,529,290
Stockholders Equity $58,595,147 $3,953,966 $4,712,338 $7,529,290
Gains Losses Not Affecting Retained Earnings $3,837,596 $2,861,283 $2,427,580 $1,770,794
Retained Earnings $-33,265,475 $-24,531,474 $-22,530,370 $-17,265,247
Other Equity Interest - $325,363 $594,082 -
Other
Ordinary Shares Number $5,453,356 $3,231,029 $2,693,952 $2,512,835
Share Issued $5,453,356 $3,231,029 $2,693,952 $2,512,835
Tangible Book Value $58,595,147 $3,953,966 $4,712,338 $7,529,290
Invested Capital $58,595,147 $3,953,966 $4,712,338 $7,529,290
Working Capital $58,544,640 $3,898,201 $4,664,907 $7,481,526
Capital Lease Obligations $89,828 $84,959 $52,527 $99,922
Total Capitalization $58,595,147 $3,953,966 $4,712,338 $7,529,290
Capital Stock $88,023,025 $25,298,794 $24,221,046 $23,023,743
Common Stock $88,023,025 $25,298,794 $24,221,046 $23,023,743
Long Term Capital Lease Obligation $29,459 $28,265 $0 $51,409
Current Capital Lease Obligation $60,369 $56,695 $52,527 $48,513
Current Accrued Expenses $386,051 $29,818 $17,855 $112,967
Net PPE $79,966 $84,029 $47,431 $99,174
Gross PPE $79,966 $84,029 $47,431 $99,174
Leases $79,966 $84,029 $47,431 $99,174
Properties $0 $0 $0 $0
Other Properties - - - $99,174
Fetched: 2026-10-24
Cash Flow Statement (Annual)
Metric 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Free Cash Flow
Free Cash Flow $-6,207,413 $-1,321,373 $-5,016,616 $-9,703,697
Operating Activities
Operating Cash Flow $-6,207,413 $-1,321,373 $-5,016,616 $-9,703,697
Cash Flow From Continuing Operating Activities $-6,207,413 $-1,321,373 $-5,016,616 $-9,703,697
Operating Gains Losses $-223,316 $-7,232 $32,387 $-184,848
Financing Activities
Issuance Of Capital Stock $58,632,742 $642,765 $869,519 $2,881,648
Financing Cash Flow $61,110,907 $578,897 $1,563,838 $3,711,034
Cash Flow From Continuing Financing Activities $61,110,907 $578,897 $1,563,838 $3,711,034
Net Other Financing Charges $-257,205 - $-19,266 $-571,332
Net Common Stock Issuance $58,632,742 $642,765 $869,519 $2,881,648
Common Stock Issuance $58,632,742 $642,765 $869,519 $2,881,648
Other
Repayment Of Debt $-71,525 $-64,084 $-61,500 $-5,115
End Cash Position $59,211,963 $4,085,196 $4,819,302 $8,304,466
Beginning Cash Position $4,085,196 $4,819,302 $8,304,466 $14,112,281
Effect Of Exchange Rate Changes $223,272 $8,370 $-32,387 $184,848
Changes In Cash $54,903,495 $-742,475 $-3,452,778 $-5,992,663
Proceeds From Stock Option Exercised $2,806,895 $216 $775,085 $1,405,833
Net Issuance Payments Of Debt $-71,525 $-64,084 $-61,500 $-5,115
Net Long Term Debt Issuance $-71,525 $-64,084 $-61,500 $-5,115
Long Term Debt Payments $-71,525 $-64,084 $-61,500 $-5,115
Change In Working Capital $396,368 $28,434 $-672,560 $517,164
Change In Payables And Accrued Expense $1,206,345 $172,827 $-855,059 $547,056
Change In Prepaid Assets $-550,838 $-134,935 $97,655 $2,698
Change In Receivables $-259,139 $-9,458 $84,844 $-32,590
Other Non Cash Items $25,604 $6,388 $14,105 $21,013
Stock Based Compensation $2,273,035 $599,751 $822,833 $624,951
Depreciation Amortization Depletion $54,898 $52,390 $51,743 $4,312
Depreciation And Amortization $54,898 $52,390 $51,743 $4,312
Depreciation $54,898 $52,390 $51,743 $4,312
Net Foreign Currency Exchange Gain Loss $-223,316 $-7,232 $32,387 $-184,848
Net Income From Continuing Operations $-8,734,001 $-2,001,104 $-5,265,123 $-10,687,717
Asset Impairment Charge - $0 $0 $1,428
Change In Other Current Liabilities - - - $1,552
Fetched: 2026-10-24